SCHEMBL4708686

SCHEMBL4708686

CCn1nc(-c2cccc(Cl)c2)c(C(C)=O)c(Nc2ccccc2F)c1=O

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 8/20 0.55
PDE4A P27815 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
PARP1 P09874 1/20 0.38
TP53 P04637 1/20 0.38
PIK3CG P48736 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171662 0.96 PDE4B (0.52) PDE4BPDE4APDE4CPDE4DHTR1A
SCHEMBL4706948 0.90 PDE4B (0.56) PDE4BPDE4APDE4CPDE4DHTR1A
SCHEMBL4706058 0.90 PDE4B (0.56) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL6176378 0.89 PDE4B (0.52) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4708773 0.89 PDE4B (0.67) PDE4BPDE4APDE4CPDE4DHTR1A
SCHEMBL4897819 0.88 PDE4A (0.49) PDE4BPDE4AHTR1AADRA1DADRA1A
SCHEMBL3038308 0.86 PDE4B (0.52) PDE4BPDE4APDE4CPDE4DPARP1
SCHEMBL4707488 0.85 PDE4B (0.59) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707865 0.85 PDE4B (0.62) PDE4BPDE4APDE4CPDE4DPARP1
SCHEMBL3032853 0.85 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885PDE4A 1/4885PDE4C 8/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885PDE4A 1/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.